Discontinued Product

L-3'-F2CCG-I (Cat. No. 1058) has been withdrawn from sale for commercial reasons.
Description: Potent group I/group II agonist
Chemical Name: (2S,1'S,2'S)-2-(2'-Carboxy-3',3'-difluorocyclopropyl)glycine
Literature (10)

Biological Activity for L-3'-F2CCG-I

Metabotropic glutamate receptor agonist, exhibits "priming" effect on the monosynaptic reflex.

Licensing Information

Sold with the permission of Nippon Chemiphar Co Ltd.

Technical Data for L-3'-F2CCG-I

M. Wt 195.12
Formula C6H7F2NO4
Storage Desiccate at +4°C
Smiles [H][C@@]1([C@](O)=O)[C@]([C@]([H])(N)C(O)=O)([H])[C@](F)1F

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for L-3'-F2CCG-I

Certificate of Analysis / Product Datasheet
Select another batch:

References for L-3'-F2CCG-I

References are publications that support the biological activity of the product.

Ishida and Shinozaki (1999) Inhibition of uptake and release of a novel mGluR agonist (L-F2CCG-I) by anion transport blockers in the rat spinal cord. Neuropharmacology 38 1531 PMID: 10530815

Saitoh et al (1998) Potentiation by DL-α-aminopimelate of a novel mGluR agonist (L-F2CCG-I) on the monosynaptic excitation in the rat spinal cord. Br.J.Pharmacol. 123 771 PMID: 9517398

Shinozaki et al (1996) Pharmacological activities of fluoride CCG derivatives: discovery of a novel agonist for metabotropic glutamate receptors. Soc.Neurosci.Abstr. 22 412.3

View Related Products by Product Action

View all Glutamate (Metabotropic) Group I Receptor Agonists

Keywords: L-3'-F2CCG-I, L-3'-F2CCG-I supplier, Potent, group, I, II, agonists, mGlur, Group, Receptors, mGlu1, mGlu5, mGluR1, mGluR5, Glutamate, Metabotropic, mGlu2, mGlu3, mGluR2, mGluR3, L-3-F2CCG-I, (Metabotropic), 1058, Tocris Bioscience

Citations for L-3'-F2CCG-I

Citations are publications that use Tocris products.

Currently there are no citations for L-3'-F2CCG-I.

Reviews for L-3'-F2CCG-I

There are currently no reviews for this product. Be the first to review L-3'-F2CCG-I and earn rewards!

Have you used L-3'-F2CCG-I?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

GPCR Product Listing

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Pain Research Product Guide

Pain Research Product Guide

A collection of over 280 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Epilepsy Poster

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Learning & Memory Poster

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Pain Poster

Pain Poster

Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.